NatiVita

en
  • Русский
  • English

NatiVita's R&D Center

Realizing the challenges and needs of people suffering from serious diseases, NatiVita's team applies its best efforts to offer efficient and yet safer medications. We are focused on personified targeted therapy of malignant tumors, as well as on mitigation of adverse drug effects and treatment of socially significant diseases.

Research programs

MABPOINT
Development of monoclonal antibody-based medications
Cancers:

Lung cancer, breast cancer, colorectal cancer, pancreatic cancer, head and neck cancer, liver cancer, haemoblastoses

Other diseases:

Rheumatoid arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, multiple sclerosis

CHEMMOTION
Development of first-in-Belarus chemical generic drugs.
Cancers:

Multiple myeloma, lung cancer, lymphocytic leukemia and lymphomas, prostate cancer

Other diseases:

Respiratory distress syndrome, pulmonary arterial hypertension, growth hormone deficiency, myocardial infarction, multiple sclerosis

Areas of research

Development of original pharmaceutical drugs

  • Engagement in drug development at the clinical testing stage, expedited registration of innovative medications.
  • Knowledge-intensive preclinical research.
  • Full cycle of innovative medication development.

Small Scale Chemical Synthesis Program

Preparation of proprietary substances for regeneration of highly efficient modern generic drugs.

Personalized Medicine

  • Cancer genome research.
  • Anticancer cell and DNA vaccines.